RegeneRx Biopharmaceuticals, Inc.

Symbol: RGRX




Market price today

  • -1.9253

    P/E Ratio

  • -0.0496

    PEG Ratio

  • 3.71M

    MRK Cap

  • 0.00%

    DIV Yield

RegeneRx Biopharmaceuticals, Inc. (RGRX) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


General Outlook

In simple terms, RegeneRx Biopharmaceuticals, Inc. has 149.697 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 1.000% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -17.757%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -24.089%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -9.898% return, is a testament to RegeneRx Biopharmaceuticals, Inc.'s adeptness in optimizing resource deployment. RegeneRx Biopharmaceuticals, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.561%. Furthermore, the proficiency of RegeneRx Biopharmaceuticals, Inc. in capital utilization is underscored by a remarkable 0.845% return on capital employed.

Stock Prices

RegeneRx Biopharmaceuticals, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.03, while its low point bottomed out at $0.01. This variance in figures offers investors a lucid insight into the roller-coaster ride that is RegeneRx Biopharmaceuticals, Inc.'s stock market.

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. J. J. Finkelstein
Full-time employees:2
Address:15245 Shady Grove Road

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.

Frequently Asked Question

How many company shares are outstanding in 2023?

There are stock number shares outstanding of RegeneRx Biopharmaceuticals, Inc. (RGRX) on the PNK in 2023.

What is P/E ratio of enterprise in 2023?

The current P/E ratio of enterprise is -1.925 in 2023.

What is the ticker symbol of RegeneRx Biopharmaceuticals, Inc. stock?

The ticker symbol of RegeneRx Biopharmaceuticals, Inc. stock is RGRX.

What is company IPO date?

IPO date of RegeneRx Biopharmaceuticals, Inc. is 2003-10-07.

What is company current share price?

Current share price is 0.025 USD.

What is stock market cap today?

The market cap of stock today is 3712485.000.

What is PEG ratio in 2023?

The current -0.050 is -0.050 in 2023.

What is the number of employees in 2023?

In 2023 the company has 2.